X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Molecular Weight | 5823 g/mol |
---|---|
Molecular Formula | C258H384N64O78S6 |
XLogP3 | -12.1 |
Hydrogen Bond Donor Count | 78 |
Hydrogen Bond Acceptor Count | 90 |
Rotatable Bond Count | 180 |
Exact Mass | 5820.6440255 g/mol |
Monoisotopic Mass | 5818.6373159 g/mol |
Topological Polar Surface Area | 2450 Ų |
Heavy Atom Count | 406 |
Formal Charge | 0 |
Complexity | 14600 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 52 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
1 of 4 | |
---|---|
Drug Name | Apidra |
Drug Label | APIDRA (insulin glulisine [rDNA origin] injection) is a rapid-acting human insulin analog used to lower blood glucose. Insulin glulisine is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12... |
Active Ingredient | Insulin glulisine recombinant |
Dosage Form | Injectable |
Route | Iv (infusion), subcutaneous |
Strength | 300 units/3ml (100 units/ml); 1000 units/10ml (100 units/ml) |
Market Status | Prescription |
Company | Sanofi Aventis Us |
2 of 4 | |
---|---|
Drug Name | Apidra solostar |
PubMed Health | Insulin Glulisine (Injection) |
Drug Classes | Antidiabetic |
Drug Label | APIDRA (insulin glulisine [rDNA origin] injection) is a rapid-acting human insulin analog used to lower blood glucose. Insulin glulisine is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12... |
Active Ingredient | Insulin glulisine recombinant |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 300 units/3ml |
Market Status | Prescription |
Company | Sanofi Aventis Us |
3 of 4 | |
---|---|
Drug Name | Apidra |
Drug Label | APIDRA (insulin glulisine [rDNA origin] injection) is a rapid-acting human insulin analog used to lower blood glucose. Insulin glulisine is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12... |
Active Ingredient | Insulin glulisine recombinant |
Dosage Form | Injectable |
Route | Iv (infusion), subcutaneous |
Strength | 300 units/3ml (100 units/ml); 1000 units/10ml (100 units/ml) |
Market Status | Prescription |
Company | Sanofi Aventis Us |
4 of 4 | |
---|---|
Drug Name | Apidra solostar |
PubMed Health | Insulin Glulisine (Injection) |
Drug Classes | Antidiabetic |
Drug Label | APIDRA (insulin glulisine [rDNA origin] injection) is a rapid-acting human insulin analog used to lower blood glucose. Insulin glulisine is produced by recombinant DNA technology utilizing a non-pathogenic laboratory strain of Escherichia coli (K12... |
Active Ingredient | Insulin glulisine recombinant |
Dosage Form | Injectable |
Route | Subcutaneous |
Strength | 300 units/3ml |
Market Status | Prescription |
Company | Sanofi Aventis Us |